Getinge and 908 Devices Join Forces for Advanced Cell Culture Monitoring

Collaboration for Continuous Monitoring in Bioprocessing

In an effort to revolutionize bioprocessing, Getinge and 908 Devices have announced a ground-breaking partnership. This collaboration aims to integrate Getinge’s innovative bioreactor technology with 908 Devices’ cutting-edge MAVEN system. The integrated solution will facilitate automated monitoring of vital cell culture parameters such as glucose and lactate levels. This ensures that researchers have continuous, real-time insights into their experiments without the inefficiencies of manual sampling.

The Importance of Monitoring Cell Culture Parameters

In bioprocessing, maintaining optimal conditions for cell culture is imperative for successful biopharmaceutical product development. Continuous monitoring of glucose and lactate not only contributes to better control of the bioreactor environment but also significantly enhances productivity. This integration is expected to reduce time to market for vital biopharmaceuticals by streamlining the processes involved.

MAVEN: A Game Changer in Bioprocess Automation

The MAVEN device developed by 908 Devices facilitates precise monitoring and control of glucose and lactate levels within bioreactors without compromising their volume. This capability is especially advantageous for biopharma scientists, enabling them to maintain necessary nutrient and metabolite concentrations efficiently, even when they are present in very low quantities. Information gathered from MAVEN can be seamlessly integrated into Getinge’s advanced control systems, allowing for precise control loops and recipe functionality, and giving scientists the ability to monitor two bioreactors simultaneously.

Expert Insights on the Collaboration

Prominent figures from both companies have expressed excitement about the potential of this partnership. Timo Keijzer, Director of Product Marketing at Getinge, stressed the benefits of this collaboration by stating, “This joint solution will significantly ease our customers’ operations in the lab, providing them with continuous visibility into concentration changes and allowing for adaptive control strategies based on real-time data.”

Christopher D. Brown, Co-founder and Chief Product Officer at 908 Devices, echoed this sentiment by emphasizing their mutual goal: “In this collaboration, we are committed to empowering our biopharma clients with advanced automation tools that enhance their understanding of processes and hasten their development timelines.”

Compatibility and Integration Enhancements

The MAVEN system is designed to interface seamlessly with Getinge’s Livit Flex controller, utilizing Livit Links sensor ports for effective connectivity. This ensures that users can easily incorporate advanced monitoring solutions into their existing setups without complication.

About Getinge

Getinge is fundamentally dedicated to ensuring that healthcare providers and life science institutions are equipped with top-notch products to improve patient care. Their extensive portfolio includes solutions for intensive care, cardiovascular procedures, operating theaters, and sterile processing. The company, employing around 12,000 professionals globally, distributes its products across more than 135 countries.

About 908 Devices

Revolutionizing chemical analysis, 908 Devices specializes in creating sophisticated handheld and desktop devices. Their technology addresses crucial applications in diverse fields including bioprocessing, life sciences research, and forensics. By leveraging a blend of analytical technologies and software automation, 908 Devices continues to lead innovation in their industry, designing products at their headquarters in Boston.

Frequently Asked Questions

What are the benefits of the Getinge and 908 Devices partnership?

This collaboration enables precise continuous monitoring of glucose and lactate levels in bioreactors, optimizing conditions for cell culture.

How does MAVEN simplify the monitoring process?

The MAVEN device allows for real-time, on-line monitoring without the need for manual sampling, thus streamlining workflows in the lab.

Who are the key figures in this partnership?

Timo Keijzer from Getinge and Christopher D. Brown from 908 Devices lead the project, emphasizing the importance of efficient bioprocessing.

What industries can benefit from this technology?

Biopharmaceuticals, life sciences, and bioprocessing sectors stand to gain significantly from the advancements made in this partnership.

What types of products does Getinge offer?

Getinge provides solutions for intensive care, operating rooms, and life sciences, focusing on enhancing clinical outcomes and workflows.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.